Trial Profile
The Cubicin Outcomes Registry and Experience (CORE), a retrospective observational record review of patients with serious Gram-positive infections treated with daptomycin in the real-world setting at 70 separate institutions in the United States from January 2005 through December 2009.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 May 2016
Price :
$35
*
At a glance
- Drugs Daptomycin (Primary)
- Indications Gram-positive infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms CORE
- 12 Apr 2016 Results of pooled analysis of CORE and EU-CORE registries (n=11557) presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
- 26 Nov 2015 New trial record